Nippon Ganka Gakkai zasshi · 2014
[The anti-inflammatory effect of 0.1% bromfenac and 0.1% betamethasone combination in post-cataract surgery patients with diabetes mellitus].
Аннотация на английскомСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Terada Yukiko, Masuda Ayami, Nejima Ryohei, Maruyama Yoko, Miyata Kazunori
Аннотация
PURPOSE: To compare the post cataract surgery anti-inflammatory effect of bromfenac monotherapy and of bromfenac and betamethasone combination therapy in diabetes mellitus patients.
METHODS: A prospective study approved by the Institutional Review Board. Fifty-one eyes of 51 patients were randomly allocated to either bromfenac 0.1% monotherapy (n = 23) or combined therapy with bromfenac 0.1% and betamethasone 0.1% (n = 28). After surgery, monotherapy group was administered bromfenac alone for 8 weeks, while the combined therapy group was administered both bromfenac and betamethasone for 2 weeks, bromfenac alone for the next 6 weeks. The amount of change from preoperative values in anterior chamber flare and foveal thickness were compared between the 2 groups.
RESULTS: There was no significant difference in change in anterior chamber flare between the 2 groups. The increase in foveal thickness 4 weeks postoperatively was significantly larger in the bromfenac group (p = 0.0356). Four patients of the bromfenac group, all with a history of diabetic macular edema, developed macular edema after surgery.
CONCLUSION: Bromfenac and betamethasone combination exhibited a stronger anti-inflammatory effect after cataract surgery patients with diabetes mellitus. In particular, patients with a history of diabetic macular edema were susceptible to foveal thickening and macular edema, and a combined treatment is desirable.
METHODS: A prospective study approved by the Institutional Review Board. Fifty-one eyes of 51 patients were randomly allocated to either bromfenac 0.1% monotherapy (n = 23) or combined therapy with bromfenac 0.1% and betamethasone 0.1% (n = 28). After surgery, monotherapy group was administered bromfenac alone for 8 weeks, while the combined therapy group was administered both bromfenac and betamethasone for 2 weeks, bromfenac alone for the next 6 weeks. The amount of change from preoperative values in anterior chamber flare and foveal thickness were compared between the 2 groups.
RESULTS: There was no significant difference in change in anterior chamber flare between the 2 groups. The increase in foveal thickness 4 weeks postoperatively was significantly larger in the bromfenac group (p = 0.0356). Four patients of the bromfenac group, all with a history of diabetic macular edema, developed macular edema after surgery.
CONCLUSION: Bromfenac and betamethasone combination exhibited a stronger anti-inflammatory effect after cataract surgery patients with diabetes mellitus. In particular, patients with a history of diabetic macular edema were susceptible to foveal thickening and macular edema, and a combined treatment is desirable.